9 Meters Biopharma Operating Income

9 Meters Biopharma's operating income stands at $-43M as of March 2023. That compares with $-43M in the prior-year period — down 1.7% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

9 Meters Biopharma reported $-43M in operating income versus $-43M a year earlier — a 1.7% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $-43M in the prior-year period — down 1.7% year over year. Sustained growth in operating income can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how 9 Meters Biopharma's operating income evolved across reporting periods, while the comparison chart places NMTR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Technology, operating income is commonly used to spot outliers. 9 Meters Biopharma's reading of $-43M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.